|
|
Volumn 27, Issue 8, 2009, Pages 679-681
|
|
JandJ's billion dollar punt on anti-amyloid antibody
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ACC 001;
AMYLOID BETA PROTEIN;
APOLIPOPROTEIN E4;
BAPINEUZUMAB;
BMS 708163;
CAD 106;
CERE 110;
DIMEBON;
DOCOSAHEXAENOIC ACID;
ELND 005;
GAMMA SECRETASE INHIBITOR;
HOMOTAURINE;
IMMUNOGLOBULIN;
IMMUNOGLOBULIN G;
LY 2062430;
MONOCLONAL ANTIBODY;
N2 [2 (3,5 DIFLUOROPHENYL) 2 HYDROXYACETYL] N1 (6,7 DIHYDRO 5 METHYL 6 OXO 5H DIBENZ[B,D]AZEPIN 7 YL)ALANINAMIDE;
NERVE GROWTH FACTOR;
NICOTINIC AGENT;
PARVOVIRUS VECTOR;
PBT 2;
PF 0449700;
PF 4360365;
R 3487;
ROSIGLITAZONE;
SOLANEZUMAB;
TARENFLURBIL;
TRX 0014;
UNCLASSIFIED DRUG;
AMYLOID;
ALZHEIMER DISEASE;
BIOTECHNOLOGY;
DRUG EFFICACY;
DRUG INDUSTRY;
DRUG MARKETING;
GENETIC RISK;
HUMAN;
INVESTMENT;
MOUSE;
NONHUMAN;
NOTE;
PATENT;
PRIORITY JOURNAL;
TRANSGENIC MOUSE;
ANIMAL;
BRAIN;
CLINICAL TRIAL;
ECONOMICS;
GENETICS;
IMMUNOLOGY;
PATHOLOGY;
ALZHEIMER DISEASE;
AMYLOID;
ANIMALS;
ANTIBODIES, MONOCLONAL;
APOLIPOPROTEIN E4;
BRAIN;
CLINICAL TRIALS AS TOPIC;
DRUG INDUSTRY;
HUMANS;
MICE;
|
|
EID: 68449094984
PISSN: 10870156
EISSN: 15461696
Source Type: Journal
DOI: 10.1038/nbt0809-679 Document Type: Note |
|
Times cited : (9)
|
|
References (0)
|
